AVXS has been the topic of several other research reports. BidaskClub raised shares of AveXis from a sell rating to a hold rating in a research note on Thursday, December 21st. Sanford C. Bernstein reaffirmed an outperform rating and issued a $144.00 price target (up previously from $110.00) on shares of AveXis in a research note on Tuesday, February 20th. Royal Bank of Canada raised their target price on shares of AveXis from $92.00 to $97.00 and gave the company a sector perform rating in a research report on Friday, November 10th. Chardan Capital reissued a buy rating and set a $135.00 target price on shares of AveXis in a research report on Friday, January 5th. Finally, UBS Group set a $122.00 price target on shares of AveXis and gave the company a buy rating in a report on Friday, January 5th. Three research analysts have rated the stock with a sell rating, three have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and an average target price of $123.90.
Shares of AveXis (NASDAQ AVXS) opened at $131.36 on Tuesday. AveXis has a twelve month low of $65.23 and a twelve month high of $138.46.
In other AveXis news, VP Andrew F. Knudten sold 2,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $118.13, for a total transaction of $236,260.00. Following the sale, the vice president now directly owns 7,000 shares in the company, valued at $826,910. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $109.72, for a total transaction of $195,301.60. Following the sale, the vice president now owns 1,780 shares in the company, valued at $195,301.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,560 shares of company stock worth $7,793,030. Corporate insiders own 18.60% of the company’s stock.
Large investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of AveXis by 57.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after buying an additional 453 shares during the period. Amalgamated Bank increased its stake in shares of AveXis by 19.6% during the third quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after buying an additional 523 shares during the period. Parametric Portfolio Associates LLC increased its stake in shares of AveXis by 2.9% during the second quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after buying an additional 598 shares during the period. Emory University increased its stake in shares of AveXis by 3.4% during the fourth quarter. Emory University now owns 18,474 shares of the company’s stock worth $2,045,000 after buying an additional 607 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of AveXis by 0.5% during the fourth quarter. Jennison Associates LLC now owns 185,094 shares of the company’s stock worth $20,484,000 after buying an additional 883 shares during the period. Institutional investors own 82.43% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Morgan Stanley Analysts Give AveXis (NASDAQ:AVXS) a $129.00 Price Target” was first posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/16/avexis-avxs-given-a-129-00-price-target-at-morgan-stanley/1987265.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.